Comments
Loading...

NeoGenomics Analyst Ratings

NEONASDAQ
Logo brought to you by Benzinga Data
$7.00
0.050.72%
At close: -
$7.07
0.071.00%
After Hours: Jun 20, 4:18 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$26.00
Lowest Price Target1
$8.50
Consensus Price Target1
$16.18

NeoGenomics Analyst Ratings and Price Targets | NASDAQ:NEO | Benzinga

NeoGenomics Inc has a consensus price target of $16.18 based on the ratings of 16 analysts. The high is $26 issued by Craig-Hallum on May 1, 2024. The low is $8.5 issued by Needham on April 29, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Morgan Stanley, and Goldman Sachs on May 6, 2025, May 1, 2025, and April 30, 2025, respectively. With an average price target of $10.67 between Piper Sandler, Morgan Stanley, and Goldman Sachs, there's an implied 50.87% upside for NeoGenomics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Jan
2
1
Feb
3
1
Apr
1
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Morgan Stanley
Goldman Sachs
Leerink Partners
Needham

1calculated from analyst ratings

Analyst Ratings for NeoGenomics

Buy NowGet Alert
05/06/2025Buy Now69.73%Piper Sandler
David Westenberg61%
$18 → $12MaintainsOverweightGet Alert
05/01/2025Buy Now41.44%Morgan Stanley
Tejas Savant51%
$17 → $10MaintainsEqual-WeightGet Alert
04/30/2025Buy Now41.44%Goldman Sachs
Matthew Sykes64%
$15 → $10MaintainsBuyGet Alert
04/30/2025Buy Now27.3%Leerink Partners
Puneet Souda56%
$25 → $9DowngradeOutperform → Market PerformGet Alert
04/29/2025Buy Now20.23%Needham
Mike Matson56%
$18 → $8.5MaintainsBuyGet Alert
04/17/2025Buy Now112.16%Goldman Sachs
Matthew Sykes64%
$17 → $15MaintainsBuyGet Alert
02/26/2025Buy Now154.6%Piper Sandler
David Westenberg61%
$21 → $18MaintainsOverweightGet Alert
02/19/2025Buy Now126.31%B of A Securities
Derik De Bruin84%
$19 → $16MaintainsNeutralGet Alert
02/19/2025Buy Now154.6%Needham
Mike Matson56%
$19 → $18MaintainsBuyGet Alert
01/28/2025Buy Now154.6%Goldman Sachs
Matthew Sykes64%
$20 → $18MaintainsBuyGet Alert
01/16/2025Buy NowBenchmark
Bruce Jackson40%
ReiteratesHold → HoldGet Alert
01/15/2025Buy Now168.74%Needham
Mike Matson56%
$19 → $19ReiteratesBuy → BuyGet Alert
01/13/2025Buy NowBenchmark
Bruce Jackson40%
DowngradeBuy → HoldGet Alert
01/10/2025Buy Now168.74%Needham
Mike Matson56%
$19 → $19ReiteratesBuy → BuyGet Alert
12/13/2024Buy Now168.74%B of A Securities
Derik De Bruin84%
$18 → $19MaintainsNeutralGet Alert
12/10/2024Buy Now211.17%Jefferies
Tycho Peterson83%
→ $22Initiates → BuyGet Alert
11/06/2024Buy Now168.74%Needham
Mike Matson56%
$19 → $19ReiteratesBuy → BuyGet Alert
09/25/2024Buy Now168.74%Needham
Mike Matson56%
$19 → $19ReiteratesBuy → BuyGet Alert
09/24/2024Buy Now154.6%Benchmark
Bruce Jackson40%
$18 → $18ReiteratesBuy → BuyGet Alert
07/30/2024Buy Now168.74%Stephens & Co.
Mason Carrico43%
$19 → $19ReiteratesOverweight → OverweightGet Alert
07/30/2024Buy Now154.6%Benchmark
Bruce Jackson40%
$18 → $18ReiteratesBuy → BuyGet Alert
07/30/2024Buy Now168.74%Needham
Mike Matson56%
$19 → $19ReiteratesBuy → BuyGet Alert
05/02/2024Buy Now197.03%BTIG
Mark Massaro71%
$23 → $21MaintainsBuyGet Alert
05/01/2024Buy Now154.6%Benchmark
Bruce Jackson40%
$18 → $18ReiteratesBuy → BuyGet Alert
05/01/2024Buy Now182.89%TD Cowen
Dan Brennan63%
$21 → $20MaintainsBuyGet Alert
05/01/2024Buy Now267.75%Craig-Hallum
Alex Nowark61%
→ $26Assumes → BuyGet Alert
04/30/2024Buy Now168.74%Needham
Mike Matson56%
$24 → $19MaintainsBuyGet Alert
02/26/2024Buy Now182.89%Piper Sandler
David Westenberg61%
$18 → $20MaintainsOverweightGet Alert
02/22/2024Buy Now168.74%Goldman Sachs
Matthew Sykes64%
$17 → $19MaintainsBuyGet Alert
02/21/2024Buy Now239.46%Needham
Mike Matson56%
$21 → $24MaintainsBuyGet Alert
12/29/2023Buy Now168.74%TD Cowen
Dan Brennan63%
$22 → $19MaintainsOutperformGet Alert
12/29/2023Buy Now197.03%BTIG
Mark Massaro71%
$25 → $21MaintainsBuyGet Alert
12/28/2023Buy Now197.03%Needham
Mike Matson56%
$21 → $21ReiteratesBuy → BuyGet Alert
11/08/2023Buy Now140.45%Morgan Stanley
Tejas Savant51%
$16 → $17MaintainsEqual-WeightGet Alert
11/07/2023Buy Now197.03%Needham
Mike Matson56%
→ $21ReiteratesBuy → BuyGet Alert
10/24/2023Buy Now126.31%Morgan Stanley
Tejas Savant51%
$18 → $16MaintainsEqual-WeightGet Alert
10/23/2023Buy Now140.45%Goldman Sachs
Matthew Sykes64%
$19 → $17MaintainsBuyGet Alert
10/20/2023Buy Now140.45%Goldman Sachs
Matthew Sykes64%
$19 → $17MaintainsBuyGet Alert
10/16/2023Buy Now154.6%Piper Sandler
David Westenberg61%
$23 → $18MaintainsOverweightGet Alert
08/21/2023Buy Now154.6%Stephens & Co.
Jacob Johnson59%
$16 → $18UpgradeEqual-Weight → OverweightGet Alert
08/09/2023Buy Now154.6%Benchmark
Bruce Jackson40%
$20 → $18MaintainsBuyGet Alert
08/09/2023Buy Now154.6%Morgan Stanley
Tejas Savant51%
$19 → $18MaintainsEqual-WeightGet Alert
08/09/2023Buy Now197.03%Needham
Mike Matson56%
→ $21ReiteratesBuy → BuyGet Alert
05/16/2023Buy NowRaymond James
Andrew Cooper54%
DowngradeOutperform → Market PerformGet Alert
05/10/2023Buy Now168.74%Morgan Stanley
Tejas Savant51%
$18 → $19MaintainsEqual-WeightGet Alert
05/09/2023Buy Now253.61%BTIG
Mark Massaro71%
→ $25UpgradeNeutral → BuyGet Alert
05/09/2023Buy Now211.17%TD Cowen
Dan Brennan63%
$20 → $22MaintainsOutperformGet Alert
05/09/2023Buy Now197.03%Needham
Mike Matson56%
→ $21Reiterates → BuyGet Alert
04/18/2023Buy Now197.03%Needham
Mike Matson56%
→ $21MaintainsBuyGet Alert
04/11/2023Buy Now140.45%B of A Securities
Derik De Bruin84%
$18 → $17MaintainsNeutralGet Alert
04/05/2023Buy Now197.03%Needham
Mike Matson56%
→ $21Reiterates → BuyGet Alert
03/03/2023Buy Now182.89%Piper Sandler
David Westenberg61%
$18 → $20MaintainsOverweightGet Alert
02/24/2023Buy Now182.89%Cowen & Co.
Dan Brennan63%
$14 → $20MaintainsOutperformGet Alert
02/24/2023Buy Now154.6%Morgan Stanley
Tejas Savant51%
$17 → $18MaintainsEqual-WeightGet Alert
02/24/2023Buy Now182.89%Benchmark
Bruce Jackson40%
→ $20UpgradeHold → BuyGet Alert
02/24/2023Buy Now168.74%Raymond James
Andrew Cooper54%
$12 → $19MaintainsOutperformGet Alert
02/24/2023Buy Now197.03%Needham
Mike Matson56%
$15 → $21MaintainsBuyGet Alert
02/01/2023Buy Now112.16%Needham
Mike Matson56%
→ $15UpgradeHold → BuyGet Alert
11/14/2022Buy Now154.6%Piper Sandler
David Westenberg61%
$19 → $18MaintainsOverweightGet Alert
11/11/2022Buy Now69.73%Raymond James
Andrew Cooper54%
$15 → $12MaintainsOutperformGet Alert
11/09/2022Buy Now140.45%Morgan Stanley
Tejas Savant51%
$18 → $17MaintainsEqual-WeightGet Alert
11/09/2022Buy Now112.16%SVB Leerink
Puneet Souda56%
$12 → $15MaintainsOutperformGet Alert
08/26/2022Buy NowBenchmark
Bruce Jackson40%
DowngradeBuy → HoldGet Alert
08/22/2022Buy NowNeedham
Mike Matson56%
DowngradeBuy → HoldGet Alert
08/17/2022Buy Now168.74%Piper Sandler
David Westenberg61%
$13 → $19MaintainsOverweightGet Alert
08/10/2022Buy Now154.6%Morgan Stanley
Tejas Savant51%
$19 → $18MaintainsEqual-WeightGet Alert
08/10/2022Buy Now182.89%Goldman Sachs
Matthew Sykes64%
$18 → $20MaintainsBuyGet Alert
08/10/2022Buy Now126.31%Needham
Mike Matson56%
$19 → $16MaintainsBuyGet Alert

FAQ

Q

What is the target price for NeoGenomics (NEO) stock?

A

The latest price target for NeoGenomics (NASDAQ:NEO) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $12.00 expecting NEO to rise to within 12 months (a possible 69.73% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for NeoGenomics (NEO)?

A

The latest analyst rating for NeoGenomics (NASDAQ:NEO) was provided by Piper Sandler, and NeoGenomics maintained their overweight rating.

Q

When was the last upgrade for NeoGenomics (NEO)?

A

The last upgrade for NeoGenomics Inc happened on August 21, 2023 when Stephens & Co. raised their price target to $18. Stephens & Co. previously had an equal-weight for NeoGenomics Inc.

Q

When was the last downgrade for NeoGenomics (NEO)?

A

The last downgrade for NeoGenomics Inc happened on April 30, 2025 when Leerink Partners changed their price target from $25 to $9 for NeoGenomics Inc.

Q

When is the next analyst rating going to be posted or updated for NeoGenomics (NEO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeoGenomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeoGenomics was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating NeoGenomics (NEO) correct?

A

While ratings are subjective and will change, the latest NeoGenomics (NEO) rating was a maintained with a price target of $18.00 to $12.00. The current price NeoGenomics (NEO) is trading at is $7.07, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.